Publication:

Asciminib-a magic bullet for chronic myeloid leukemia with T315I mutation: a case series

Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm typically characterized by the presence of the Philadelphia chromosome. The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of most CML patients. However, resistance to TKIs poses a significant challenge, leading to poor treatment outcomes and prognosis in some patients. Fortunately, the introduction of asciminib, a novel allosteric BCR-ABL1 inhibitor, has provided a ray of hope. We present three cases in this report that highlight the remarkable efficacy of asciminib seen in our patients. All of these patients initially responded positively to conventional TKIs but developed a T315I mutation in the BCR-ABL fusion protein during their chemotherapy, rendering conventional TKIs ineffective and resulting in loss of response. Asciminib led to the achievement of a major molecular response in all of our patients.